• Publications
  • Ensuring sustained incentives for pharma to d...
Publication - published on 06 Jun 2016

Ensuring sustained incentives for pharma to develop medicine for the poor

A commentary by Clarke B. Cole and Jayasree K. Iyer, explores the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of R&D models in incentivising these contributions.

This article details how pharma companies engage with the Product Development Partnership (PDP) model and other models that are based on the combined principles of open collaboration and access to medicine.




Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.